Repurposing Drugs for Inflammation and Infectious Diseases
This Revive Therapeutics profile is part of a paid investor education campaign.*
The company is currently focused on developing IP and treatments for infectious diseases, including potential treatments using psilocybin, along with a portfolio of cannabis-based IP with a focus on autoimmune hepatitis and ischemia. The company recently announced it is exploring the use of the drug bucillamine as a potential novel treatment for infectious diseases including influenza and the side effects of the coronavirus disease (COVID-19). Revive has applied for a provisional patent with the US Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases”. Revive already has Phase 2 status for the treatment of gout with bucillamine.
In March of 2020, Revive Therapeutics announced that Dr. David Boulware was joining the company as a Scientific Advisor to guide on its current and future clinical programs including its research and development strategy for infectious diseases.
Dr. Boulware is an infectious disease physician-scientist and Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota. Dr. Boulware is currently the Principal Investigator of a globally recognized COVID-19 clinical trial to determine if post-exposure prophylaxis with hydroxychloroquine can prevent progression development of symptomatic COVID-19 disease after known exposure to the SARS-CoV2 virus (ClinicalTrials.gov Identifier: NCT04308668). His primary research interests are in meningitis in resource-limited areas including diagnosis, prevention, treatment, and quality improvement initiatives incorporating cost-effectiveness analyses in order to translate knowledge into improved care. Dr. Boulware’s current research is focused on improving the clinical outcomes of HIV-infected persons with cryptococcal meningitis and TB meningitis. Dr. Boulware has active research collaborations in Uganda, South Africa, and Ethiopia leading a multidisciplinary, international research team. He serves on US and WHO panels for cryptococcal meningitis and WHO panels for advanced HIV disease.
In the past, Revive Therapeutics has received orphan drug status from the US Food and Drug Administration (FDA) for the use of cannabidiol (CBD) in the treatment of ischemia and reperfusion injury from organ transplantation. Revive Therapeutics is also working to leverage the anti-inflammatory properties of CBD in the treatment of autoimmune hepatitis. The company has a patent for the use of CBD in the treatment of Autoimmune Hepatitis (liver disease) and also has a patent pertaining to the use of bucillamine in the treatment of gout.
Through the company’s acquisition of Psilocin Pharma Corp., Revive Therapeutics is working to develop a portfolio of psychedelic therapies using novel delivery methods including hard-shell capsules, oral strips, gumdrop compositions and sublingual formulations. Psilocin has developed a portfolio of patent-pending formulations for the active compound psilocybin which the company intends to apply towards the treatment of depression, anxiety, bi-polar disorder, bulimia, anorexia nervosa and a number of other diseases pending FDA approval.
- Filed provisional patent applications for novel psilocybin delivery systems including tablets, oral compositions, hard-shell capsules, gumdrops, oral strips and sublingual and buccal administration.
Revive Therapeutics’ Patent Portfolio
Revive Therapeutics is developing a patent portfolio including several drugs with the potential to be applied to a variety of disorders. The company has secured patents pertaining to the use of Bucillamine for the treatment of Gout (US 9238018B2), cannabidiol for the treatment of Autoimmune Hepatitis (US 8242178) and a trio of novel cannabinoid delivery systems., as well as psilocybin-based IP.
This includes provisional patents for novel psilocybin delivery systems including tablets, oral compositions, hard-shell capsules, gumdrops, oral strips and sublingual and buccal administration.
Psilocin Pharma Corp
Psilocin Pharma Corp is a drug development company that has developed several potential treatments based on the active compound psilocybin. The company’s treatments have been designed to work with the body’s natural pathways of absorption, leveraging more contemporary delivery methods including hard-shell capsules, oral strips, gumdrop compositions and sublingual formulations.
Revive Therapeutics finalized the acquisition of Psilocin Pharma Corp in March of 2020. Moving forward, Revive intends to leverage Psilocin’s portfolio of psilocybin-based compounds. The company has six patents pending pertaining to psilocybin-based formulations and delivery methods:
- Solid Oral Pharmaceutical Compositions, United States Provisional Application Serial No. 62/985,052 – Psilocybin effervescent and psilocybin tablet designed to be placed under the tongue or dissolved in water. Allowing for improved taste and controlled release profiles.
- Pharmaceutical Capsule Compositions, United States Provisional Application Serial No. 62/985,070 – Psilocybin hard-shell capsules containing dry, powdered ingredients in 2-piece capsules. Allowing for contemporary consumption familiar to the user (Gelatin and vegetarian enclosure options in addition to unique nutrient delivery combination options).
- Pharmaceutical Gumdrop Compositions, United States Provisional Application Serial No. 62/985,084 – Psilocybin gumdrops for improved administration of compounds. Offers unique delivery methods for fat and water-soluble options.
- Thin-Film Pharmaceutical Delivery System and Formulations, United States Provisional Application Serial No. 62/985,098 – Psilocybin oral strips and psilocybin transmucosal delivery system. Proprietary oral fast-dissolving drug delivery system rapidly releases though the buccal pathway.
- Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration, United States Provisional Application Serial No. 62/984,590 – Formulation for spray/pump/dosing pen.
Derrick Welsh, the founder of Psilocybin Pharma, has 14 years of experience in the healthcare industry including five years in the cannabis industry. Welsh has direct experience developing patent-pending formulations including water-soluble THC and CBD products such as water enhancers and effervescent tablets. Welsh has previously worked with publicly traded cannabis companies such as Green Growth Brands (CSE:GGB, OTCQB:GGBXF).
Revive Therapeutics’ Management Team
Michael Frank, Chairman and Chief Executive Officer
Mr. Michael Frank is the Chairman of the Board and CEO of Revive. Mr. Frank has a strong background in operations, business development, M&A and the capital markets. Mr. Frank is currently the President of Mifran Consulting, providing advisory services to emerging technology companies in a number of key verticals. In the past, Mr. Frank has served as the CEO and Director of Sprylogics International and the Internet of Things Inc., as well as holding senior management positions at Ernst & Young, Data General, and NCR. Mr. Frank has had successful exits in the technology sector including one to Intuit Corporation, and has been instrumental in advising several early-stage software companies including a number in the cannabis sector over the last few years. Additionally, Mr. Frank has consulted to Revive’s senior management team on various strategic initiatives.
Carmelo Marrelli, Chief Financial Officer
Mr. Marrelli holds a Bachelor of Commerce degree from the University of Toronto and is qualified as a Chartered Accountant and as a Certified General Accountant in Canada. Mr. Marrelli has been a principal of Marrelli Support Services Inc., a firm providing administration services to Canadian public companies, since February 2009 and, prior to February 2009, a partner with Marrelli & Drake Corporate Services (formerly Duguay & Ringler Corporate Services) (a firm providing administration services to Canadian public companies). Mr. Marrelli also serves as the Chief Financial Officer of several publicly-listed junior mining companies and as a director of Odyssey Resources Limited, an Exchange listed issuer.
William Jackson, Director
William Jackson is currently Chief Executive Officer of Atwill Medical Solutions. Mr. Jackson was a cofounder of Covalon Technologies Ltd. (TSXV:COV) and held senior management roles such as Chief Financial Officer, Chief Operating Officer and Chief Business Officer, and director from December 2004 to January 2013. Mr. Jackson served as a director of Titan Medical Inc. (TSXV:TMD) from April 2008 to June 2010.
Joshua Herman, Director
Mr. Joshua Herman, a director of the Company, is the Chief Executive Officer of Herman Holdings Limited. Mr. Herman was a corporate accountant at Hennick Herman for 8 years where he focused on advising clients on various transactional, accounting and tax issues. In 2015, Mr. Herman began early-stage investing in the medical marijuana industry, where he has since become a prolific and well-known investor. In 2017, Mr. Herman founded Herman Holdings in order to capitalize on the top investment opportunities he has access to within the cannabis space.
Christian Scovenna, Director
Mr. Christian Scovenna is a highly-experienced C-Suite Executive with over twelve years of capital market experience. In his most recent engagement with Mojave Jane Brands Inc. (formerly, High Hampton Holdings Corp.) (CSE: JANE), he was instrumental in building the company as one of the original founders and was a key member of the management team as interim CEO and Senior VP Corporate Finance while also serving on the board as a director. As Managing Director at a boutique firm, Mr. Scovenna led six portfolio companies within the group where he focused on raising capital and business development.
Andrew Lindzon, Director
Mr. Andrew Lindzon, a director of the Company, is a seasoned professional and investor with an excellent track record. He earned an LLB from Osgoode Hall (1984) and is CEO of Ashlin Technology Solutions since 1985. Ashlin provides North American companies with technology products and services to improve business processes.
This profile is sponsored by Revive Therapeutics Ltd. (CSE:RVV). This profile provides information which was sourced by the Investing News Network (INN) and approved by Revive Therapeutics, in order to help investors learn more about the company. Revive Therapeutics is a client of INN. The company’s campaign fees pay for INN to create and update this profile.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Revive Therapeutics and seek advice from a qualified investment advisor.